Intravitreal ranibizumab for patients with neovascular age-related macular degeneration with good baseline visual acuity

Intravitreal ranibizumab for patients with neovascular age-related macular degeneration with good baseline visual acuity - Intravitreal ranibizumab for patients with neovascular AMD with good baseline VA

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015073

Enrollment

Registered

2014-09-09

Start date

2013-01-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neovascular age-related macular degeneration

Interventions

intravitreal ranibizumab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) diagnosed with neovasulular AMD by OCT 2) baseline logMAR BCVA of 0.22 or better

Exclusion criteria

Exclusion criteria: 1) the patients who were undergone previous treatment such aslaser photocoagulation, intravitreal triamcinolone, intravitreal anti VEGF or photodynamic therapy. 2) the patients who were undergone vitrectomy 3) the patients who has allergy for fluorescein and indocyanine green

Design outcomes

Primary

Measure	Time frame
best-corrected visual acuities	—

Secondary

Measure	Time frame
central retinal thickness	—

Countries

Japan

Contacts

Public ContactAki Kato

Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan Department of Ophthalmology and Visual Science

akikato@med.nagoya-cu.ac.jp052-853-8251

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026